Genpact (G)

NYSEIndustrialsInformation Technology ServicesSnapshot 2026-10-23

$40.83-2.27%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Genpact’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-0.1%

+10% or more+5%0%−5%−10% or less

4.51 → 4.51 EPS · FY ending Dec 31, 2027 · 9 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 9 to 9; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q3
EPS	$1.04–$1.05non-GAAP	—
Gross margin	About 36.6%	—
Revenue growth	At least 25%	—
FY 2026 · Q4
Revenue	—	1.42B
EPS	—	1.097
FY 2026 · Annual
Revenue	—	5.44B
EPS	—	4.121
Eps growth	At least 12%non-GAAP	—
Revenue growth	At least 25%	—
FY 2027 · Annual
Revenue	—	5.82B
EPS	—	4.51

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Achieve EPS near $4.04 in 2026	A supporting condition in Genpact's published investment case. The stated target is >=4.04 USD per share.	Intact	EPS falls below $4.04 in FY26	Diluted EPS: $0.86 per share FY2026-Q2; GAAP. Published target: >=4.04 USD per share. Target period is not explicitly aligned with this observation. Source published Aug 7, 20260.86 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 206bafa9-b449-4eeb-99c0-837ef7dbb035. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Revenue grew from $1.254 billion in 2025-Q2 to $1.343 billion in 2026-Q2, a 7.1% year-over-year increase, consistent with full year 2025 growth of 6.6%. Management's guidance and actual revenue growth show the company is delivering on this growth target. Delivery assessment Oct 24, 2026
Maintain adjusted operating margin near 17.7% in 2026	A primary condition in Genpact's published investment case. The stated target is >=17.7%.	Broken	Operating margin falls below 17.7% in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 4 of last 4 quarters. Adjusted income from operations margin improved from 17.4% in 2026-Q1 to 17.8% in 2026-Q2, consistent with full year 2025 margin of approximately 17.7%. Management's recurring guidance and actual margin expansion indicate delivery on this operational efficiency priority. Delivery assessment Oct 24, 2026
Net revenue growth at least 7% in 2026	A primary condition in Genpact's published investment case. The stated target is >=7% YoY.	Under Pressure	YoY revenue growth falls below 7% in FY26	Revenue growth: 7.1% FY2026-Q2; GAAP. Published target: >=7% YoY. Target period is not explicitly aligned with this observation. Source published Aug 7, 20267.096518 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 206bafa9-b449-4eeb-99c0-837ef7dbb035. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Revenue grew from $1.254 billion in 2025-Q2 to $1.343 billion in 2026-Q2, a 7.1% year-over-year increase, consistent with full year 2025 growth of 6.6%. Management's guidance and actual revenue growth show the company is delivering on this growth target. Delivery assessment Oct 24, 2026
Maintain valuation discount vs peers	A supporting condition in Genpact's published investment case. The stated target is PE below 15.	Intact	PE rises above 15 without earnings growth	P/E (TTM): 10.72x As of 2026-10-23; trailing twelve months. The target timing and basis require a separate assessment. Market data as of Oct 23, 202610.7165 ratio · calculatedLast status assessment Oct 24, 2026 Measurement source consolidated · TTM valuation Period ending Oct 23, 2026 Source: mart.stock_valuation_daily. Reference: G:2026-10-23. Source status: canonical calculation. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$4.51

$4.48 → $4.51 · observed estimates

FY2027 revenue$5.82B

$5.83B → $5.82B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$4.48	$5,833,098,170	12 / 12
2026-07-25	$4.48	$5,833,098,170	12 / 12
2026-07-26	$4.48	$5,833,098,170	12 / 12
2026-07-27	$4.48	$5,833,086,469	9 / 9
2026-07-28	$4.48	$5,833,098,170	12 / 12
2026-07-29	$4.48	$5,833,086,469	9 / 9
2026-07-30	$4.48	$5,833,098,170	12 / 12
2026-07-31	$4.48	$5,833,086,469	9 / 9
2026-08-01	$4.48	$5,833,086,469	9 / 9
2026-08-02	$4.48	$5,833,086,469	9 / 9
2026-08-03	$4.48	$5,833,098,170	12 / 12
2026-08-04	$4.48	$5,833,098,170	12 / 12
2026-08-05	$4.48	$5,833,098,170	12 / 12
2026-08-06	$4.48	$5,833,098,170	12 / 12
2026-08-07	$4.48	$5,833,086,469	9 / 9
2026-08-08	$4.49	$5,830,937,690	12 / 11
2026-08-09	$4.49	$5,830,937,690	12 / 11
2026-08-10	$4.49	$5,830,937,690	12 / 11
2026-08-12	$4.48	$5,833,086,469	9 / 9
2026-08-13	$4.48	$5,833,086,469	9 / 9
2026-08-14	$4.48	$5,833,086,469	9 / 9
2026-08-15	$4.48	$5,833,086,469	9 / 9
2026-08-16	$4.48	$5,833,086,469	9 / 9
2026-08-17	$4.48	$5,833,086,469	9 / 9
2026-08-18	$4.48	$5,833,086,469	9 / 9
2026-08-19	$4.48	$5,833,086,469	9 / 9
2026-08-20	$4.51	$5,823,246,137	9 / 9
2026-08-21	$4.51	$5,823,246,137	9 / 9
2026-08-22	$4.51	$5,823,246,137	9 / 9
2026-08-23	$4.51	$5,823,246,137	9 / 9
2026-08-24	$4.51	$5,823,246,137	9 / 9
2026-08-25	$4.51	$5,823,246,137	9 / 9
2026-08-26	$4.51	$5,823,246,137	9 / 9
2026-08-27	$4.51	$5,823,246,137	9 / 9
2026-08-28	$4.51	$5,823,246,137	9 / 9
2026-08-29	$4.51	$5,823,258,531	9 / 9
2026-08-30	$4.51	$5,823,258,531	9 / 9
2026-08-31	$4.51	$5,823,258,531	9 / 9
2026-09-01	$4.51	$5,823,258,531	9 / 9
2026-09-02	$4.51	$5,823,258,531	9 / 9
2026-09-03	$4.51	$5,823,258,531	9 / 9
2026-09-04	$4.51	$5,823,258,531	9 / 9
2026-09-05	$4.51	$5,823,258,531	9 / 9
2026-09-06	$4.51	$5,823,258,531	9 / 9
2026-09-07	$4.51	$5,823,258,531	9 / 9
2026-09-08	$4.51	$5,823,258,531	9 / 9
2026-09-09	$4.51	$5,823,255,056	9 / 9
2026-09-10	$4.51	$5,823,255,056	9 / 9
2026-09-11	$4.51	$5,823,255,056	9 / 9
2026-09-12	$4.51	$5,823,255,056	9 / 9
2026-09-13	$4.51	$5,823,255,056	9 / 9
2026-09-14	$4.51	$5,823,255,056	9 / 9
2026-09-15	$4.51	$5,823,255,056	9 / 9
2026-09-16	$4.51	$5,823,255,056	9 / 9
2026-09-17	$4.51	$5,823,255,056	9 / 9
2026-09-18	$4.51	$5,823,255,056	9 / 9
2026-09-19	$4.51	$5,823,255,056	9 / 9
2026-09-20	$4.51	$5,823,255,056	9 / 9
2026-09-21	$4.51	$5,823,255,056	9 / 9
2026-09-22	$4.51	$5,823,255,056	9 / 9
2026-09-23	$4.51	$5,823,255,056	9 / 9
2026-09-24	$4.51	$5,823,255,056	9 / 9
2026-09-25	$4.51	$5,823,255,056	9 / 9
2026-09-26	$4.51	$5,823,255,056	9 / 9
2026-09-27	$4.51	$5,823,255,056	9 / 9
2026-09-28	$4.51	$5,823,255,056	9 / 9
2026-09-29	$4.51	$5,823,255,056	9 / 9
2026-09-30	$4.51	$5,823,255,056	9 / 9
2026-10-01	$4.51	$5,823,255,056	9 / 9
2026-10-02	$4.51	$5,823,255,056	9 / 9
2026-10-03	$4.51	$5,823,255,056	9 / 9
2026-10-04	$4.51	$5,823,255,056	9 / 9
2026-10-05	$4.51	$5,823,255,056	9 / 9
2026-10-06	$4.51	$5,823,255,056	9 / 9
2026-10-07	$4.51	$5,823,255,056	9 / 9
2026-10-08	$4.51	$5,823,255,056	9 / 9
2026-10-09	$4.51	$5,823,255,056	9 / 9
2026-10-10	$4.51	$5,823,255,056	9 / 9
2026-10-11	$4.51	$5,823,255,056	9 / 9
2026-10-12	$4.51	$5,823,255,056	9 / 9
2026-10-13	$4.51	$5,823,255,056	9 / 9
2026-10-14	$4.51	$5,823,188,389	9 / 9
2026-10-15	$4.51	$5,823,188,389	9 / 9
2026-10-16	$4.51	$5,823,188,389	9 / 9
2026-10-17	$4.51	$5,823,188,389	9 / 9
2026-10-18	$4.51	$5,823,188,389	9 / 9
2026-10-19	$4.51	$5,823,188,389	9 / 9
2026-10-20	$4.51	$5,823,188,389	9 / 9
2026-10-21	$4.51	$5,823,188,389	9 / 9
2026-10-22	$4.51	$5,823,188,389	9 / 9
2026-10-23	$4.51	$5,823,188,389	9 / 9
2026-10-24	$4.51	$5,821,136,972	9 / 9

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	5	7
2026-06-01	5	7
2026-07-01	5	7
2026-08-01	5	7
2026-09-01	5	7
2026-10-01	5	7

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 5 Buy / Strong Buy · 7 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

SusquehannaOct 22 · prior May 5

$37.00 → $40.00+8.1%

$0$22.00$44.00

1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Achieve EPS near $4.04 in 2026Diluted EPS: $0.86 per share
Maintain adjusted operating margin near 17.7% in 2026Published status: Broken
Net revenue growth at least 7% in 2026Published status: Under Pressure
Maintain valuation discount vs peersP/E (TTM): 10.72x

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.4%Typical daily move · historical

Downside history

-43.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Genpact outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This investment represents a durable compounder with a focus on steady revenue growth and operational efficiency. The current thesis state is intact, but recent events, such as a CFO transition, introduce some uncertainty.

What's priced into Genpact

The stock is currently priced cheaply compared to its peers, reflecting a low expectations gap. The market seems to account for the company's fragile earnings quality, which may limit downside but also suggests caution.

What the fundamentals likely do

Management is on track to achieve its growth targets, including a 7% revenue growth and a 25% increase in Advanced Technology Solutions revenue. However, the near-term risk remains elevated due to the potential for misses in guidance, especially as industry peers have struggled recently.

What Genpact hinges on

The thesis hinges on the performance of sector bellwethers like BR, LDOS, and CACI. If these companies continue to perform well, it could support G's growth. Conversely, any negative guidance from these peers could pose risks to G's performance.